Doctors are cautious about linking weight loss drug tirzepatide to the death of a nurse in Scotland. Susan McGowan took tirzepatide for two weeks before her death, with pancreatitis and septic shock listed on her death certificate. Medical experts believe it may be difficult to prove if tirzepatide caused her death. Trials of tirzepatide have not shown a higher risk of pancreatitis, and the drug was approved in the UK last year. The manufacturer, Eli Lilly, emphasizes patient safety. The NHS plans to rollout tirzepatide in England, prioritizing patients with the greatest need. The Medicines and Healthcare products Regulatory Agency encourages reporting of any suspected side effects of tirzepatide.
Source link
Doctors Caution Over Weight Loss Drug Link to Nurse’s Death
